Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 7.74%
March 31, 2026 10.52%
December 31, 2025 8.88%
September 30, 2025 9.16%
June 30, 2025 8.41%
March 31, 2025 11.05%
December 31, 2024 9.98%
September 30, 2024 9.25%
June 30, 2024 8.82%
March 31, 2024 11.26%
December 31, 2023 10.26%
September 30, 2023 10.25%
June 30, 2023 9.65%
March 31, 2023 11.26%
December 31, 2022 10.64%
September 30, 2022 10.66%
June 30, 2022 9.53%
March 31, 2022 11.40%
December 31, 2021 9.95%
September 30, 2021 10.39%
June 30, 2021 9.73%
March 31, 2021 11.35%
December 31, 2020 11.24%
September 30, 2020 10.95%
June 30, 2020 10.08%
Date Value
March 31, 2020 10.79%
December 31, 2019 9.78%
September 30, 2019 10.81%
June 30, 2019 9.42%
March 31, 2019 11.57%
December 31, 2018 9.95%
September 30, 2018 10.23%
June 30, 2018 10.07%
March 31, 2018 11.28%
December 31, 2017 11.17%
September 30, 2017 10.82%
June 30, 2017 10.88%
March 31, 2017 11.32%
December 31, 2016 10.70%
September 30, 2016 11.10%
June 30, 2016 10.28%
March 31, 2016 12.53%
December 31, 2015 11.35%
September 30, 2015 12.10%
June 30, 2015 11.66%
March 31, 2015 12.47%
December 31, 2014 13.10%
September 30, 2014 13.15%
June 30, 2014 12.76%
March 31, 2014 12.92%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
AS ONE Corp. 30.90%
Henry Schein, Inc. 29.81%
Accendra Health, Inc. 37.62%
Fuse Medical, Inc. --
Medipal Holdings Corp. 6.29%